Rapid Reactions

Rapid Reactions

Updates on 1L Maintenance Therapy with PARP Inhibitors for Advanced Ovarian Cancer
Dr David M. O’Malley, Professor, Department of Obstetrics and Gynecology at The Ohio State University College of Medicine and Director of the Division of Gynecologic Oncology at the OSUCCC – James, discusses his perspectives on the current treatment landscape and optimal clinical management of patients with advanced ovarian cancer who are given PARP-is as maintenance therapy in the first-line setting. More Information ›

Underserved Patients with HER2-Positive mBC
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, highlights and addresses potential barriers of clinically and demographically underserved patients with HER2-positive mBC. More Information ›

Treatment Landscape and Clinical Management of HER2-Positive mBC
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, discusses his perspectives on the current treatment landscape and clinical management of HER2-positive mBC. More Information ›

HER2-Positive mBC Trials in Progress
Dr. Neil M. Iyengar, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, reports on current trials in progress in patients with HER2-positive mBC with and without the presence of brain metastasis. More Information ›

Unmet Needs Still Persist for Women with Metastatic Breast Cancer
Despite recent advances in treatment, metastatic breast cancer (mBC) remains one of the leading causes of cancer-related deaths in the United States among women. And the prevalence of mBC has also been increasing. In the United States, almost 170,000 women were estimated to be living with the disease in 2020. Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, discusses how he manages his patients with metastatic recurrence following first-line therapy. More Information ›

HER2Climb Study Represents an Important Breakthrough for Patients with HER2-positive Metastatic Breast Cancer
The long-term results of the HER2Climb trial, which compared TUKYSA® (tucatinib) to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (mBC) with and without brain metastases, were presented at ASCO this year. The results generated a significant amount of interest among physicians who manage women with HER2-positive mBC. Please join Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, as he discusses some of the pivotal data from the HER2Climb trial at ASCO this year. More Information ›

Important New Data on Metastatic Breast Cancer from ASCO 2021
ASCO 2021 is in the rearview mirror but there were plenty of highlights, especially regarding metastatic breast cancer. Please join Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, as he discusses some interesting data from key metastatic breast cancer trials from the ASCO meeting. More Information ›

Subscribe Today!

To sign up for our free e-Newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM e-Newsletter
OPM print publication